Bavarian Nordic A/S develops, manufactures, and supplies life-saving vaccines. The company offers non-replicating smallpox and monkeypox vaccines under the IMVAMUNE, IMVANEX, and JYNNEOS names; rabies vaccine for human use under the Rabipur/RabAvert name; tick-borne encephalitis vaccine under the Encepur name; Vaxchora, an oral vaccine for immunization against cholera; and Vivotif/Typhoral, an oral vaccine for immunization against typhoid fever. It is also developing MVA-BN WEV for the treatment of encephalitis viruses. It operates in the United States, Denmark, Canada, France, Germany, Singapore, Finland, Netherlands, Switzerland, Sweden, Taiwan, Saudi Arabia, Belgium, and internationally. Bavarian Nordic A/S was incorporated in 1992 and is headquartered in Hellerup, Denmark.
Metrics to compare | BAVA | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipBAVAPeersSector | |
---|---|---|---|---|
P/E Ratio | 13.1x | −4.6x | −0.6x | |
PEG Ratio | 0.13 | −0.09 | 0.00 | |
Price/Book | 1.5x | 2.5x | 2.6x | |
Price / LTM Sales | 2.9x | 13.9x | 3.3x | |
Upside (Analyst Target) | 2.2% | 190.2% | 38.0% | |
Fair Value Upside | Unlock | −1.5% | 4.4% | Unlock |